ERAS pathways are not a single intervention but a coordinated bundle of evidence-based practices that touch every phase of the surgical journey. They typically include thorough pre-operative counseling about recovery milestones, a preference for minimally invasive surgical techniques, avoidance of routine nasogastric tubes, multimodal pain control built around intravenous nonsteroidal anti-inflammatory drugs and acetaminophen rather than opioids alone, early removal of urinary catheters, early mobilization out of bed, rapid advancement of oral intake, and clearly defined discharge targets. The concept, first popularized in colorectal surgery, rests on a simple physiological insight: the traditional rituals of post-operative care, such as prolonged bed rest, bowel rest, and drainage tubes, often do more harm than good, delaying the return of normal gut function and prolonging hospitalization.

Despite widespread adoption in colon and rectal surgery, ERAS programs for gastrectomy have lagged behind, and prospective evaluations in diverse American patient populations have been scarce. Most of the existing evidence comes from European and Asian centers, where gastric cancer surgery is performed at higher volumes and patient demographics differ considerably. The new study was designed to fill that gap. The investigators registered their trial at ClinicalTrials.gov in August 2018 and prospectively enrolled patients undergoing distal subtotal or total gastrectomy with either prophylactic or curative intent at City of Hope National Medical Center in Duarte, California. Of 78 patients with gastric cancer screened, 51 were enrolled and received structured pre-operative counseling on each element of the ERAS pathway before their operations.

The surgical mix reflected modern practice at a high-volume cancer center. Roughly 41 percent of enrolled patients underwent distal subtotal gastrectomy, in which the distal portion of the stomach is removed, while 59 percent underwent total gastrectomy, a more extensive operation requiring reconstruction of the digestive tract. A striking 80 percent of the procedures were performed robotically, with the remaining 20 percent done through an open approach. This heavy reliance on minimally invasive technique is itself one of the eight ERAS elements the team tracked, reflecting evidence that smaller incisions and less tissue trauma translate into faster recovery of bowel function and less post-operative pain.

The eight elements selected for the pathway were deliberately concrete and measurable. They included a pre-operative discussion about recovery milestones, a preference for minimally invasive surgery, avoidance of nasogastric tubes, post-operative intravenous NSAIDs or acetaminophen, early removal of the urinary catheter, early mobilization, early diet advancement, and a defined post-operative discharge day. The primary endpoint was discharge by post-operative day five for distal subtotal gastrectomy patients and by post-operative day six for total gastrectomy patients. Secondary endpoints included patient-reported quality of life, measured with validated European Organisation for Research and Treatment of Cancer quality of life questionnaires, and the reasons for any deviations from the pathway.

The results were encouraging. Median length of stay was 4.5 days for distal subtotal gastrectomy patients and 5.4 days for total gastrectomy patients, figures that compare favorably with historical norms for these operations. Among patients discharged at least 24 hours after their target discharge date, 86 percent of distal subtotal gastrectomy patients, 18 of 21, had adhered to the ERAS elements, compared with 71 percent of total gastrectomy patients, 22 of 31. Notably, every patient in the study was discharged directly home rather than to a rehabilitation facility or skilled nursing unit, an outcome that underscores the functional recovery the pathway is designed to promote.

The clearest signal in the data concerned complications. Twelve of the 51 patients, or 24 percent, experienced post-operative complications, and these patients had significantly lower adherence to the ERAS elements. Among patients with complications, 81 percent experienced delays in discharge, a relationship that was highly statistically significant. This finding cuts in two directions. On one hand, it suggests that complications remain the dominant force pushing patients off the pathway and keeping them in the hospital. On the other hand, it reinforces the value of adherence itself: patients who could follow the pathway largely did go home on schedule, and deviations clustered around clinical setbacks rather than arbitrary failures of the protocol.

Perhaps the most patient-centered finding came from the quality of life analysis. Global quality of life scores were preserved six months after gastrectomy, indicating that patients overall sense of well-being returned to pre-operative levels. Sub-categories told a more nuanced story. Physical functioning, fatigue, and pain all initially declined in the early post-operative period, as any patient who has undergone major abdominal surgery would expect, but these domains recovered by six months after the operation. For a procedure as invasive as total gastrectomy, demonstrating that patient-reported well-being rebounds to baseline within half a year is a meaningful benchmark, and it provides surgeons and patients alike with concrete expectations for the recovery arc.

The study population was also notable for its ethnic diversity, an important consideration given that gastric cancer incidence and outcomes vary substantially across racial and ethnic groups in the United States. The investigators argue that their findings demonstrate the feasibility of delivering a standardized, procedure-specific ERAS pathway in an ethnically diverse U.S. population, achieving high adherence to discharge targets while preserving quality of life. They caution, however, that this was a single-center prospective trial, and they call for prospective multicenter validation of complete ERAS programs to confirm the results more broadly.

For the surgical oncology community, the trial adds a missing piece of evidence. Randomized controlled trials comparing full ERAS bundles against conventional care are difficult to run, because the components of these pathways are individually well supported and withholding them raises ethical concerns. Prospective adherence studies like this one, which enroll patients, counsel them on the pathway in advance, track compliance with each element, and link adherence to hard outcomes such as length of stay, complications, and quality of life, offer a practical alternative. The message from this trial is that when a cancer center commits to the full bundle, from pre-operative education to early feeding and mobilization, stomach cancer patients can expect to be home in under a week and feeling like themselves again within months. As ERAS programs continue to spread through surgical oncology, studies of this kind provide the roadmap for implementing them well, and the benchmarks against which future programs should be judged.

Subject of Research: Adherence to an enhanced recovery after surgery pathway following gastrectomy for gastric cancer, with surgical outcomes and quality-of-life endpoints

Article Title: Prospective evaluation of adherence to an enhanced recovery pathway after gastrectomy at a U.S. comprehensive cancer center: surgical outcomes and quality-of-life endpoints

Article References: Prospective evaluation of adherence to an enhanced recovery pathway after gastrectomy at a U.S. comprehensive cancer center: surgical outcomes and quality-of-life endpoints. (n.d.). https://doi.org/10.1186/s12885-026-17097-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17097-6

Keywords: ERAS, gastrectomy, gastric cancer, enhanced recovery after surgery, quality of life, minimally invasive surgery, robotic surgery, length of stay, surgical oncology, post-operative care, prospective trial, BMC Cancer